GP

Goldline Pharmaceutical

GLPL BSE
Price unavailable

Key Fundamentals

SME
Market Cap
₹31.20 Cr
P/E (TTM)
10.16
EBITDA
₹6.90 Cr
Return on Equity
28.89%
Debt to Equity
0.88
Book Value
₹25.05
EPS (TTM)
₹3.20
52W High
₹60.00
52W Low
₹28.50

Price-based figures as of 12 Oct 2026, 15:30 IST · TTM

Peer Comparison

Sun Pharma
₹1,770.7035.134,24,850 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,285.0084.272,46,488 Cr14.710.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,642.9072.891,76,601 Cr21.000.82%12.16%9.06%15,391 Cr2,156 Cr
Zydus Life Science
₹1,132.5025.201,12,967 Cr4.170.09%16.99%19.24%28,515 Cr4,593 Cr
Cipla
₹1,329.6031.851,07,413 Cr3.121.00%11.21%14.88%28,786 Cr3,356 Cr
Mankind Pharma
₹2,372.0047.9597,974 Cr6.010.04%11.70%13.78%15,074 Cr2,067 Cr
Lupin
₹1,953.6016.1589,336 Cr3.980.92%23.79%28.42%30,017 Cr5,552 Cr
Goldline Pharmaceutical (this company)
—10.1631 Cr1.300.00%28.89%39.98%17 Cr3 Cr
Goldline Pharmaceutical
—————————
Median 9 companies₹1,953.6033.491,10,190 Cr4.630.57%14.56%18.45%21,953 Cr3,141 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

No Tapetide Score has been computed for this stock yet.

Technical Indicators

Oscillators

BearishNeutralBullish

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

BearishNeutralBullish

Bearish

Bearish
7
Neutral
9
Bullish
3

Moving Averages

BearishNeutralBullish

Bearish

Bearish
5
Neutral
4
Bullish
1

Growth Rate

Revenue Growth
11.03% lower than 3Y

change over 1 year

Net Income Growth
46.43% lower than 3Y

change over 1 year

Cash Flow Change
-11.64%

change over 1 year

EBITDA Margin Change
7.02%

change over 1 year Operating margin 24.9% · Mar 2026

Quarterly Results

Particulars Sep 2025Mar 2026
Sales
13.89
17.31
Expenses
11.25
13
Operating Profit
2.64
4.31
OPM %
19.01%
24.9%
Other Income
0
0
Interest
0.67
0.65
Depreciation
0.12
0.12
PBT
1.85
3.54
Tax %
26.49%
21.75%
Net Profit
1.36
2.76
EPS (₹)
1.97
4
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
19.73
23.48
28.01
31.18
Expenses
17.32
19.14
21.86
24.09
Operating Profit
2.41
4.34
6.15
7.09
OPM %
12.21%
18.48%
21.96%
22.74%
Other Income
-0.2
-0.04
-0.09
0
Interest
1.63
1.61
1.95
1.46
Depreciation
0.18
0.16
0.25
0.24
PBT
0.4
2.53
3.86
5.39
Tax %
37.5%
28.46%
26.42%
23.38%
Net Profit
0.26
1.81
2.83
4.12
EPS (₹)
1.3
7.87
4.1
5.97
Div. Payout %
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2.3
6.9
6.9
Reserves
2.08
3.76
1.55
5.54
Borrowings
12.64
12.94
12.85
10.97
Other Liabilities
2.67
3.93
4.88
5.47
Total Liabilities
19.39
22.93
26.18
28.88
Fixed Assets
2.5
2.95
2.89
2.71
CWIP
0
0.45
0
0
Investments
0.07
0.03
0.03
0.03
Other Assets
16.82
19.5
23.26
26.14
Total Assets
19.39
22.93
26.18
28.88
Figures in ₹ Crores

Cash Flow

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2.39
2.92
3.18
2.81
Investing
-1.04
-1.11
0.16
-0.06
Financing
-1.44
-1.08
-2.89
-3.4
Net Cash Flow
-0.09
0.74
0.45
-0.65
Free Cash Flow
1.38
1.81
3.35
2.75
CFO/OP
101
72
66
53
Figures in ₹ Crores

Ratios

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
160
150
139
189
Inventory Days
336
450
229
202
Days Payable
54.47
98.62
69.62
60.29
Cash Conversion Cycle
441
501
299
331
Working Capital Days
144
133
134
156
ROCE %
—
23.4%
29.28%
30.64%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Goldline Pharmaceutical insights

29 extracted metrics + investor summaries across FY23–FY26.

Log in — free

Shareholding Pattern

Promot.79.71%Others20.29%As ofSep 2025
A trend needs at least two reported periods.

Documents

Frequently Asked Questions about Goldline Pharmaceutical

Where is Goldline Pharmaceutical (GLPL) listed?
Goldline Pharmaceutical trades under code GLPL on the BSE.
What is the market capitalisation of Goldline Pharmaceutical?
Goldline Pharmaceutical has a market capitalisation of ₹31.2 Cr as of 12 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Goldline Pharmaceutical?
Goldline Pharmaceutical trades at a PE ratio of 10.16 as of 12 Oct 2026, on earnings per share of ₹3.2, against a book value of ₹25.05 per share.
What is the 52-week high and low of Goldline Pharmaceutical?
Over the last 52 weeks Goldline Pharmaceutical has traded between ₹28.5 and ₹60 as of 12 Oct 2026.
What is the Return on Equity (ROE) of Goldline Pharmaceutical?
Goldline Pharmaceutical reported a return on equity of 28.89%. Its debt-to-equity ratio is 0.88.

Company Information

Shares Outstanding 96,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLPL.md for Goldline Pharmaceutical: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List